Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.2680
+0.0007 (+0.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
August 10, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study...
Via
FinancialNewsMedia
Topics
Supply Chain
Exposures
Supply Chain
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report
August 09, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Is It Safe to Smoke DMT?
July 14, 2022
Via
Investor Brand Network
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Toronto Firm Receives First Federal Government Funding to Study Psilocybin
August 08, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
August 03, 2022
Via
Investor Brand Network
New Poll Finds Most Americans Support Research on Psychedelics for Military Members
August 03, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
Study Finds That Difficulty Sleeping, Financial Stressors Increase Mental Health Risk in University Students
August 02, 2022
Via
Investor Brand Network
Research Finds Psychedelics May Open Door to Self-Actualization
July 29, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference
July 28, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants
July 28, 2022
Via
Investor Brand Network
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 28, 2022
From
Cybin Inc.
Via
Business Wire
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
July 27, 2022
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Research Suggests How Individuals Can Control Unwanted Thoughts
July 26, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting
July 26, 2022
Via
Investor Brand Network
Cybin Announces Date of Annual Meeting of Shareholders
July 25, 2022
From
Cybin Inc.
Via
Business Wire
What You Should Know, Do Before Investing in Psychedelics Stocks
July 25, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study
July 25, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow
July 20, 2022
Via
Investor Brand Network
House Approves Amendments on Psychedelic Therapy in Defense Spending Measure
July 20, 2022
Via
Investor Brand Network
Online Companies Offering Mental Health Services Come Under Spotlight
July 13, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment
July 12, 2022
Via
Investor Brand Network
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
July 12, 2022
From
Clinilabs Drug Development Corporation
Via
Business Wire
Congressional Leaders Want Studies to be Conducted on Mental Health Benefits of Psychedelics
July 11, 2022
Via
Investor Brand Network
Topics
Law Enforcement
Exposures
Legal
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
July 11, 2022
Via
Investor Brand Network
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
July 11, 2022
From
Cybin Inc.
Via
Business Wire
Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals
July 06, 2022
Via
Investor Brand Network
New Study Finds That Probiotics May Be Useful in Fight Against Depression
July 05, 2022
Via
Investor Brand Network
NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision
June 29, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.